PHARMACOKINETICS OF VORICONAZOLE DURING CONTINUOUS VENOVENOUS HEMODIAFILTRATION - Voriconazole during CVVHDF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-003479-35-AT

Enrollment

Registered

2005-11-28

Start date

2006-01-02

Completion date

Unknown

Last updated

2013-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Patients with proven or suspected infection with fungal pathogens requiring parenteral therapy with voricaonzole who are undergoing continuous venovenous hemodiafiltration

Interventions

Trade Name: Vfend 200 mg Pulver zur Herstellung einer Infusionslösung Product Name: Vfend Pharmaceutical Form: Powder for infusion*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: requirement of another extracorporal therapy rather than CVVHDF hypersensitivity or other intolerance to voriconazole patients receiving terfenadine, astemizole, cisapride, primozide, quinidine, sirolimus, rifampin, rifabutin, efavirenz, carbamazepine, long-acting barbiturates, ritonavir, phenytoin, ergot alkaloids women of childbearing potential

Design outcomes

Primary

Measure	Time frame
Main Objective: We want to study the pharmacokinetics of voriconazole in critically ill patients with proven or suspected fungal infection requiring parenteral therapy with voriconazole who are undergoing continuous venovenous hemodiafiltration, to establish a dosage recommendation in this patient collective.;Secondary Objective: ;Primary end point(s): pharmacokinetic analysis	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026